Glaxo receives FDA 'complete response' for cervical cancer vaccine

Armen Hareyan's picture
Advertisement

GlaxoSmithKline (NYSE: GSK) announced today that it has received a complete response letter from the U.S. Food and Drug Administration related to its application for the cervical cancer vaccine, CERVARIX

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement